Health Technology Assessment: New Opportunity to Apply for Joint Scientific Consultations

Please see the below information regarding EU joint Health Technology Assessment, with particular focus on joint Pharma, MD/IVD scientific advice meetings, for joint clinical assessments.

Health Technology Assessment: New Opportunity to Apply for Joint Scientific Consultations

Today, the Commission has opened the first submission period for joint scientific consultations (JSCs) for 2026. This is the third submission period under the EU Health Technology Assessment Regulation, after its entry into application on 12 January 2025. Two submission periods were concluded last year with a total of seven JSCs selected, of which four are already finalised.

JSCs enable health technology developers (pharma and medtech companies) to consult with the Health Technology Assessment agencies in the Member States on how their clinical studies should be conducted to best prepare for a potential Joint Clinical Assessment.

The submission period is open from 7 January to 4 February 2026 to developers of both medicines and medical devices. There is no fee for this service.

Health technology developers can also request the JSC to be carried out in parallel with the European Medicines Agency’s (EMA) scientific advice. This means that the meeting with the health technology developer and the individual experts is a joint meeting with the EMA, their scientific advice coordinators and their experts.

Developers can apply for the following consultation slots during this request period:

· Briefing document by 07 April 2026

· Briefing document by 04 May 2026

· Briefing document by 08 June 2026

Requests must be uploaded to the HTA IT Platform by 4 February 2026. As access to the platform can take a few days, early registration is recommended. Please see here how to submit a request.